U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07325357) titled 'Effect of Pirfenidone on TA Fibrosis' on Nov. 27, 2025.
Brief Summary: Takayasu arteritis is a severe vasculitis which could lead to significant disability and even death. While standard anti-inflammatory treatments can manage the systemic inflammation, they failed to stop a key driver of the disease: vascular fibrosis. This fibrosis could result in blood vessels thickening and narrowing, which continues to progress in many patients.
To tackle this critical treatment gap, the present project explores a new strategy. Building on pirfenidone's success in treating fibrosis in organs just like lungs and liver, along with promising early...